We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Hydroquinoneis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Hydroquinone studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality meta-analyses and randomised trials published 2003–2024 with a typical study size of 40 participants.
Based on 8 studies · 1 meta-analysis · 2 RCTs · 682 total participants
Confidence
ModerateBy outcome
Hydroquinone has an evidence score of 7/10 — strong evidence based on 8 indexed studies, including 1 meta-analysis. The long-standing gold-standard topical skin-lightening agent for melasma and hyperpigmentation — and now a regulated drug, not a cosmetic. Hydroquinone (HQ) competitively inhibits tyrosinase and is toxic to overactive pigment cells. The honest framing: it is the most rigorously studied and most effective topical depigmenter — a large pivotal RCT, a Cochrane review, and recent meta-analyses all use HQ 4% (and the 'Kligman' triple-combination with a retinoid + steroid) as the benchmark that newer agents are measured against and rarely beat. But it carries real liabilities: irritation, rebound pigmentation, and — with prolonged or high-strength use — a disfiguring complication called exogenous ochronosis. For these reasons it was pulled from US over-the-counter sale in 2020 (now prescription-only) and is restricted in the EU and elsewhere. Effective, but for monitored, time-limited medical use. Representative study: PMID 39673630.
Practical, evidence-based guides that cover Hydroquinone.
Explore: Best supplements for Skin, Hair & Beauty
Last reviewed June 2026 · evidence from 8 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Hydroquinone (topical depigmenting agent)
The long-standing gold-standard topical skin-lightening agent for melasma and hyperpigmentation — and now a regulated drug, not a cosmetic. Hydroquinone (HQ) competitively inhibits tyrosinase and is toxic to overactive pigment cells. The honest framing: it is the most rigorously studied and most effective topical depigmenter — a large pivotal RCT, a Cochrane review, and recent meta-analyses all use HQ 4% (and the 'Kligman' triple-combination with a retinoid + steroid) as the benchmark that newer agents are measured against and rarely beat. But it carries real liabilities: irritation, rebound pigmentation, and — with prolonged or high-strength use — a disfiguring complication called exogenous ochronosis. For these reasons it was pulled from US over-the-counter sale in 2020 (now prescription-only) and is restricted in the EU and elsewhere. Effective, but for monitored, time-limited medical use.
The most rigorously studied and most effective topical depigmenter — a pivotal RCT (n=641), a Cochrane review, and recent meta-analyses all treat hydroquinone 4% (and the Kligman triple-combination) as the gold-standard benchmark newer agents rarely beat; held below the top by short-term/heterogeneous efficacy data, rebound, and real safety liabilities (irritation, exogenous ochronosis) that made it prescription-only.
Hydroquinone (benzene-1,4-diol) is the historical gold-standard topical treatment for melasma and other forms of hyperpigmentation.
It is a regulated drug, not a cosmetic: in the United States it was removed from over-the-counter sale by the 2020 CARES Act and is now available only by prescription, and it is restricted or banned in cosmetics in the EU and many other markets.
Mechanistically, HQ competitively inhibits tyrosinase (the rate-limiting enzyme of melanin synthesis) and is oxidised within melanocytes into reactive quinones that are selectively cytotoxic to the overactive pigment cells — a dual depigmenting action. The efficacy evidence is the strongest in the category.
A pivotal pooled multicenter RCT (Taylor et al., 2003; n=641) showed the triple-combination cream (hydroquinone 4% + tretinoin 0.05% + fluocinolone 0.01%, the 'Kligman/Tri-Luma' formula) cleared melasma far more than the dual combinations, and a 2023 double-blind RCT confirmed the hydroquinone Kligman trio as the gold standard whose efficacy 'has never been matched.' A Cochrane systematic review found the triple-combination outperformed hydroquinone alone (RR 1.58) and all dual combinations, and recent meta-analyses of newer agents (azelaic acid, cysteamine) use HQ 4% as the reference comparator they fail to significantly surpass.
The honest, mandatory counter-evidence is about safety: prolonged or high-strength HQ can cause exogenous ochronosis — a paradoxical, cosmetically disfiguring blue-black darkening that is difficult to treat — alongside irritant dermatitis and rebound hyperpigmentation on discontinuation.
These liabilities, plus theoretical concerns, drove its move to prescription/regulated status. So the honest summary: hydroquinone clearly works and remains the benchmark depigmenter, but it should be used at ≤4% for limited periods with clinician monitoring and sun protection — not indefinitely.
None of this is a cosmetic claim. It is listed under Beauty & Appearance so it is discoverable, but is sandboxed out of ingestible-supplement stacks and the schedule optimizer; it carries a prescription-drug badge and a topical-only disclaimer.
Hydroquinone competitively inhibits tyrosinase, the rate-limiting enzyme of melanin synthesis, reducing pigment production. This is the primary depigmenting mechanism it shares with milder agents, but HQ is the most potent of them clinically.
Within melanocytes, hydroquinone is oxidised to reactive quinones that are selectively toxic to overactive pigment cells. This adds to its potency — but the same reactive chemistry underlies irritation and, with prolonged use, the risk of exogenous ochronosis.
Prescription topical. Hydroquinone is used at 2-4% (often as the triple-combination with a retinoid and a mild corticosteroid), applied to pigmented areas usually at night, in time-limited courses (commonly with treatment breaks) under clinician supervision, always with daily sunscreen. There is no oral or systemic use. Avoid indefinite continuous use because of ochronosis risk. This library does not provide an ingestion protocol.
| Form | Type |
|---|---|
| 🧴Hydroquinone 2-4% cream or the triple-combination (with retinoid + mild steroid), under a clinician | Recommended |
| 🍵Non-hydroquinone depigmenters (azelaic acid, cysteamine, tranexamic acid) for maintenance or when HQ is unsuitable | Alternative |
There is no oral or injectable form. Hydroquinone is prescription-only in the US and restricted/banned in cosmetics elsewhere.
Minimum: 8 weeks
Optimal: 12 weeks
Cycling: Used in time-limited courses (commonly ~3-4 months) with treatment breaks or a switch to non-hydroquinone maintenance, specifically to reduce the risk of exogenous ochronosis with continuous long-term use.
Note: Applied to pigmented areas (often at night), in time-limited courses with breaks, plus daily sunscreen. As a topical there is no ingestion or meal-timing consideration.
Hydroquinone is the most effective topical agent for melasma/hyperpigmentation, but it is prescription-only in the US (since 2020) and restricted elsewhere. Use it under a clinician, time-limited, not as an everyday cosmetic.
Lightens melasma and hyperpigmentation more effectively than other topicals, especially as the triple-combination (with a retinoid and a mild steroid).
Causes irritant dermatitis (redness, burning, peeling), and pigmentation can rebound when treatment stops — which is why it is cycled and paired with strict sun protection.
Long-term or high-concentration use can cause exogenous ochronosis — a paradoxical, disfiguring blue-black darkening that is hard to treat. Use ≤4% for limited periods with monitoring, and stop immediately if it appears.
Generally avoided in pregnancy — hydroquinone has notable systemic absorption; azelaic acid is usually preferred. Consult a clinician.
Effective but higher reported rates of exogenous ochronosis with prolonged use; use time-limited under dermatologist supervision with sun protection.
Do not use indefinitely — cycle with breaks/maintenance agents and monitor for ochronosis; this is a key reason it is now prescription-controlled.
Hydroquinone can oxidise and temporarily stain skin brown when combined with peroxides; separate their use. This is a formulation consideration, not a systemic interaction — it is not ingested.
Combining with other irritants increases dermatitis risk; the triple-combination deliberately pairs HQ with a retinoid and a mild steroid under supervision.
Tip: Use as directed in time-limited courses; reduce frequency or pause if irritation is significant.
Tip: Avoid prolonged/high-strength use; discontinue immediately if blue-black darkening appears, as it is difficult to treat.
Tip: Transition to non-hydroquinone maintenance and strict sun protection rather than stopping abruptly without a plan.
The commonly studied dose of Hydroquinone is Prescription topical. Hydroquinone is used at 2-4% (often as the triple-combination with a retinoid and a mild corticosteroid), applied to pigmented areas usually at night, in time-limited courses (commonly with treatment breaks) under clinician supervision, always with daily sunscreen. There is no oral or systemic use. Avoid indefinite continuous use because of ochronosis risk. This library does not provide an ingestion protocol.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Hydroquinone is in the evening. It can be taken on an empty stomach. Hydroquinone is a leave-on topical commonly applied at night (often with a retinoid in the triple-combination) and paired with morning sunscreen; there is no meal-timing relationship.
Hydroquinone should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are irritant/contact dermatitis (redness, burning, peeling), exogenous ochronosis (paradoxical darkening), rebound hyperpigmentation after stopping. Use caution if any of these apply to you: For topical (skin) use only — not for ingestion, not for injection; Prolonged continuous or high-strength use (ochronosis risk) — use time-limited courses; Known allergy/sensitivity to hydroquinone.
Commonly recommended vs ask-your-clinician vs avoid — a general, safety-first overview.